Source-grounded facts extracted from CYTOKINETICS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CYTOKINETICS INC shareholders approved Advisory Vote on Executive Compensation at the 2026-05-27 meeting.
“The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company's Proxy Statement for the 2026 Annual Meeting of Stockholders.”
CYTOKINETICS INC shareholders approved Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026 at the 2026-05-27 meeting.
“The stockholders ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
CYTOKINETICS INC shareholders approved Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance under the Amended and Restated 2015 Employee Stock Purchase Plan by 1,000,000 shares of common stock at the 2026-05-27 meeting.
“The stockholders approved the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan.”
CYTOKINETICS INC shareholders approved Election of Three Class I Directors at the 2026-05-27 meeting.
“The stockholders elected Edward M. Kaye, M.D., Wendell Wierenga, Ph.D., and Nancy J. Wysenski as Class I Directors, each to serve for a three-year term and until their successors are duly elected and qualified or their earlier resignation or removal.”
CYTOKINETICS INC reported first quarter of 2026 results: revenue $19.4 million.
“Cash, cash equivalents and investments declined by approximately $144 million during the first quarter of 2026. Revenues • Total revenues for the first quarter of 2026 were $19.4 million, compared to $1.6 million for the same period in 2025. Total revenues in the first quarter of 2026 include: o $4.8 million MYQORZO net product revenue which represents”
CYTOKINETICS INC issued 2,168,806 shares of the common stock of common stock.
“The 2,168,806 shares of the common stock being issued in connection with the Note Exchange Transactions are being issued in reliance on the exemption from the registration requirements provided by Section 4(a)(2) of the Securities Act.”
CYTOKINETICS INC issued up to 15,072,300 shares of the Company's common stock of common stock.
“Initially, a maximum of 15,072,300 shares of the Company's common stock may be issued upon conversion of the Notes”
CYTOKINETICS INC issued convertible note to initial purchasers for $750.0 million aggregate principal amount.
“On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.”
CYTOKINETICS INC incurred convertible notes of $750.0 million aggregate principal amount with initial purchasers at 1.75% per year maturing October 1, 2031.
“On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.”
Robert E. Landry was appointed as Director at CYTOKINETICS INC.
“On February 10, 2025, (the “ Effective Date ”), the Board of Directors (the “ Board ”) of Cytokinetics, Incorporated (the “ Company ”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert E. Landry to fill a vacant Board seat and to serve as a Class II member of the Board with an initial term expiring at the Company’s 2027 annual meeting of stockholders.”
Santo J. Costa resigned as Director at CYTOKINETICS INC.
“On November 1, 2024, Santo J. Costa notified Cytokinetics, Incorporated (the "Company") of his resignation from the Board of Directors of the Company (the "Board of Directors"), with immediate effect.”
Brett Pletcher was appointed as Executive Vice President, Chief Legal Officer at CYTOKINETICS INC.
“On August 13, 2024, Cytokinetics, Incorporated (the “Company”) entered into an employment offer letter (the “Offer Letter”) with Brett Pletcher, pursuant to which Mr. Pletcher has agreed to serve as the Company’s Executive Vice President, Chief Legal Officer, effective as of August 19, 2024 (the “Start Date”).”
CYTOKINETICS INC shareholders approved Advisory Vote on Executive Compensation.
“Proposal 4: Advisory Vote on Executive Compensation The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the 2024 Proxy Statement. The votes were as follows: For Against Abstain Broker Non-Vote 85,814,395 2,927,007 790,693 6,649,555”
CYTOKINETICS INC shareholders approved Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 at the 2024-12-31 meeting.
“Proposal 3: Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 The stockholders ratified the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were as follows: For Against Abstain 95,957,265 97,750 126,635”
CYTOKINETICS INC shareholders approved Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock..
“Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555”
CYTOKINETICS INC shareholders approved Election of Two Class II Directors.
“Proposal 1: Election of Two Class II Directors The stockholders elected Robert I. Blum and Robert A. Harrington, M.D. as Class II Directors, each to serve for a three-year term and until their successors are duly elected and qualified or their earlier resignation or removal. The voting for each director was as follows: Name For Withheld Broker Robert I. Blum 87,317,169 2,214,926 6,649,555 Robert A. Harrington, M.D. 78,347,186 11,184,909 6,649,555”
Sandford D. Smith resigned as Director at CYTOKINETICS INC.
“On May 15, 2024, Sandford D. Smith notified Cytokinetics, Incorporated (the “Company”) of his resignation from the Board of Directors of the Company (the “Board of Directors”), with such resignation effective immediately before the 2024 annual meeting of stockholders of the Company held on May 15, 2024 (the “Annual Meeting”).”
CYTOKINETICS INC reported first quarter of 2024 results: net income Net loss for the first quarter was $135.6 million, or $1.33 per share.
“Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2024. Net loss for the first quarter was $135.6 million, or $1.33 per share, compared to net loss for the first quarter of 2023 of $131.3 million, or $1.38 per share.”
Sung H. Lee was appointed as Executive Vice President, Chief Financial Officer at CYTOKINETICS INC.
“On April 23, 2024, Cytokinetics, Incorporated (the “Company”) entered into an employment offer letter (the “Offer Letter”) with Sung H. Lee, pursuant to which Mr. Lee has agreed to serve as the Company’s Executive Vice President (“EVP”), Chief Financial Officer, effective as of May 8, 2024 (the “Start Date”).”
CYTOKINETICS INC reported the fourth quarter and full year 2023 results: net income Net loss for the fourth quarter was $136.9 million or $1.38 per share and the net loss for the year 2023 was $526.2 mill.
“On February 27, 2024, Cytokinetics, Incorporated announced its financial results for the fourth quarter and for the year ended December 31, 2023.”
Ching W. Jaw resigned as Senior Vice President & Chief Financial Officer at CYTOKINETICS INC.
“On January 29, 2024, Ching W. Jaw, Senior Vice President & Chief Financial Officer, informed Cytokinetics, Incorporated (the "Company") that he would be resigning his office and employment with the Company effective February 23, 2024.”
CYTOKINETICS INC: Amended and restated bylaws to update advance notice provisions, universal proxy rule compliance, proxy color requirement, stockholder meeting conduct, and conform to Delaware law (effective 2023-11-16).
“On and effective as of November 16, 2023, the Board of Directors (the “Board”) of Cytokinetics, Incorporated (the “Company”) approved and adopted an amendment and restatement of the Amended and Restated Bylaws of the Company (as so amended and restated, the “Revised Bylaws”)”
CYTOKINETICS INC reported third quarter ended September 30, 2023 results: net income $129.4 million, EPS $1.35 per share.
“Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third quarter of 2023. Net loss for the third quarter was $129.4 million, or $1.35 per share, compared to net loss for the third quarter of 2022 of $142.3 million, or $1.52 per share.”
CYTOKINETICS INC updated its 2023 guidance (lowered).
“The company today revised its financial guidance due to the reduction in expected operating expenses following the receipt of a CRL from the FDA regarding the New Drug Application for omecamtiv mecarbil and the discontinuation of COURAGE-ALS, the Phase 3 trial of reldesemtiv. The company anticipates operating expenses for 2023 will be in the range of $390 to $410 million”
CYTOKINETICS INC updated its second quarter of 2023 guidance (reaffirmed).
“On August 3, 2023, Cytokinetics, Incorporated (the "Registrant") announced its financial results for the second quarter ended June 30, 2023.”
CYTOKINETICS INC shareholders approved Advisory Vote on Frequency of "Say on Pay" Proposal at the 2023-05-10 meeting.
“The stockholders approved, on an advisory basis, 1-Year as the frequency with which the stockholders of the Company wish to have an advisory vote on the compensation of the Company’s named executive officers as disclosed pursuant to the SEC’s compensation disclosure rules (which disclosure includes the Compensation Discussion and Analysis, the related compensation tables and the narrative disclosure to those tables in the Company’s proxy statement).”
CYTOKINETICS INC shareholders approved Advisory Vote on Executive Compensation at the 2023-05-10 meeting.
“The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company’s Proxy Statement for the 2023 Annual Meeting of Shareholders.”
CYTOKINETICS INC shareholders approved Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023 at the 2023-05-10 meeting.
“The stockholders ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
CYTOKINETICS INC shareholders approved Approval of an Amendment to the Company’s Amended and Restated Certificate of Incorporation to Permit the Exculpation of the Senior Officers of the Company at the 2023-05-10 meeting.
“The stockholders approved the Amendment to the Company’s Amended and Restated Certificate of Incorporation to permit the exculpation of the senior officers of the Company.”
CYTOKINETICS INC shareholders approved Approval of an Amendment to the Company’s Amended and Restated Certificate of Incorporation to Permit Director Exculpation at the 2023-05-10 meeting.
“The stockholders approved the Amendment to the Company’s Amended and Restated Certificate of Incorporation to permit director exculpation.”
CYTOKINETICS INC shareholders approved Election of Three Class I Directors at the 2023-05-10 meeting.
“The stockholders elected Edward M. Kaye, M.D., Wendell Wierenga, Ph.D. and Nancy J. Wysenski as Class I Directors, each to serve for a three-year term and until their successors are duly elected and qualified or their earlier resignation or removal.”
CYTOKINETICS INC reported the first quarter ended March 31, 2023 results: net income $131.3 million, EPS $1.38 per share.
“Net loss for the first quarter was $131.3 million, or $1.38 per share, compared to net loss for the first quarter of 2022 of $89.4 million, or $1.05 per share.”
CYTOKINETICS INC reported the fourth quarter and full year 2022 results: net income Net loss for the fourth quarter was $137.4 million or $1.45 per share and the net loss for the year 2022 was $389.0 mill.
“On March 1, 2023, Cytokinetics, Incorporated announced its financial results for the fourth quarter and for the year ended December 31, 2022.”
CYTOKINETICS INC: Added Article X providing exclusive forum selection provisions and renumbered existing Article X to Article XI (effective 2023-02-14).
“On and effective as of February 14, 2023, the Board of Directors (the “Board”) of Cytokinetics, Incorporated approved and adopted Amended and Restated Bylaws of Cytokinetics (the “Revised Bylaws”) for the purposes of: (a) renumbering Article X thereof to be Article XI, and (b) adding a new Article X thereof (i) to provide that, unless Cytokinetics consents in writing to the selection of an alternative forum, specified courts in Delaware shall be the exclusive forum for resolving certain disputes under corporate law, and the federal district courts of the United States shall be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, to the fullest extent permitted by law, and (c) to make certain technical revisions as set forth therein.”
CYTOKINETICS INC amended Second Amendment to Development Funding Loan Agreement with Royalty Pharma Development Funding, LLC (effective 2022-12-08).
“The Amendment extends the deadline dates, from December 31, 2022, to March 31, 2023, for which each of the respective conditions of the Tranche 2 Term Loans and Tranche 3 Term Loans must occur in order for Cytokinetics to be able to draw on these loans.”
CYTOKINETICS INC reported third quarter of 2022 results: net income Net loss for the third quarter was $142.3 million, EPS $1.52 per share.
“Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third quarter of 2022. Net loss for the third quarter was $142.3 million, or $1.52 per share”
Mark A. Schlossberg retired as Senior Vice President, Legal, General Counsel and Secretary at CYTOKINETICS INC.
“On April 12, 2022, Mark A. Schlossberg, Senior Vice President, Legal, General Counsel and Secretary of Cytokinetics, Incorporated, informed Cytokinetics that he would be retiring from Cytokinetics effective May 13, 2022.”
John T. Henderson was appointed as Chairman of the Board at CYTOKINETICS INC.
“As a result of Dr. Gage’s resignation, John T. Henderson, M.D. was appointed as Chairman of the Board.”
L. Patrick Gage resigned as Director at CYTOKINETICS INC.
“Also on the Effective Date, L. Patrick Gage, Ph.D. resigned as a director of Cytokinetics.”
Robert A. Harrington was appointed as Director at CYTOKINETICS INC.
“On April 8, 2022, (the “Effective Date”), the Board of Directors (the “Board”) of Cytokinetics, Incorporated (the “Company”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert A. Harrington, M.D. to fill a vacant Board seat and to serve as a member of the Board with an initial term expiring at the Company’s 2024 annual meeting of stockholders.”
Robert M. Califf resigned as Director at CYTOKINETICS INC.
“On February 16, 2022, Robert M. Califf, a member of the Board of Directors of Cytokinetics, Incorporated, resigned as a director of Cytokinetics effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.